Forest Labs and Gedeon Richter have evaluated the investigational NR2B-selective NMDA (N-methyl D-aspartate) receptor antagonist, Radiprodil (RGH-896) in the clinical trial for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPNP).
Radiprodil was discovered by Gedeon Richter and is currently being co-developed with Forest Laboratories as a candidate for the treatment of chronic neuropathic pain conditions, including neuropathic pain caused by diabetes mellitus.
Forest Laboratories has licensed US and Canadian rights for Radiprodil from Gedeon Richter.
Forest Labs and Gedeon Richter said that they would review the complete study database over the coming weeks to determine the appropriate next steps regarding the development of radiprodil.